Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Buserelin, Atc L02ae01 for the Period January 1St, 2024 - December 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Insulin Lispro, Atc A10ab04, A10ad04 F. D. Time 01/01/24 - 12/31/24 (Plus Extension Option 1X12 Months)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Formoterol Beclometasone (Exclusively Dafo. Dos), Atc R03ak08 for the Period January 1St, 2024 - December 31St, 2025

Open House Drug Discount Agreements Tocilizumab, Atc L04ac07

Open House Drug Discount Contracts Testosterone, Atc G03ba03

Medicines Called Xeomin(R) (Atc: M03ax21)

Medicines with the Active Ingredient Ciclosporin (Atc: S01xa18)

Medicines with the Active Ingredient Tafluprost (Atc: S01ee05)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Formoterol Beclometasone (Exclusively Dafo. Ihp, Inh), Atc R03ak08 for the Period January 1St, 2024 - December 31St, 2025

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredients Mentioned with the Possibility of Conclusion as Part of the So-Called Open House Procedure.